S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom

Virax Biolabs Group (VRAX) Competitors

$0.69
+0.04 (+6.17%)
(As of 04/17/2024 ET)

VRAX vs. CANOQ, SPRC, TCBP, ACOR, BDRX, SIENQ, NVTA, AKAN, EVFM, and CMRA

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Cano Health (CANOQ), SciSparc (SPRC), TC Biopharm (TCBP), Acorda Therapeutics (ACOR), Biodexa Pharmaceuticals (BDRX), Sientra (SIENQ), Invitae (NVTA), Akanda (AKAN), Evofem Biosciences (EVFM), and Comera Life Sciences (CMRA). These companies are all part of the "medical" sector.

Virax Biolabs Group vs.

Virax Biolabs Group (NASDAQ:VRAX) and Cano Health (NYSE:CANOQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Cano Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Virax Biolabs Group has higher earnings, but lower revenue than Cano Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K106.62-$5.46MN/AN/A
Cano Health$3.14B0.00-$594.42M-$215.870.00

In the previous week, Virax Biolabs Group had 2 more articles in the media than Cano Health. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Cano Health. Virax Biolabs Group's average media sentiment score of 1.02 beat Cano Health's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company Overall Sentiment
Virax Biolabs Group Positive
Cano Health Neutral

Virax Biolabs Group and Cano Health both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Virax Biolabs GroupN/AN/A
Cano HealthN/AN/A

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 38.0% of Cano Health shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 13.9% of Cano Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Virax Biolabs Group has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Cano Health has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500.

Virax Biolabs Group has a net margin of 0.00% compared to Cano Health's net margin of -18.94%. Virax Biolabs Group's return on equity of 0.00% beat Cano Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Cano Health -18.94%-133.59%-43.85%

Summary

Virax Biolabs Group beats Cano Health on 9 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$1.07M$2.53B$4.78B$7.41B
Dividend YieldN/A0.79%2.90%3.97%
P/E RatioN/A182.11250.1619.03
Price / Sales106.6292.512,347.8587.82
Price / CashN/A13.2648.2735.34
Price / Book0.123.664.634.20
Net Income-$5.46M$30.88M$102.55M$212.41M
7 Day Performance-11.81%-5.82%-4.84%-4.60%
1 Month Performance-18.01%-8.81%-4.40%-3.16%
1 Year Performance-88.60%-30.55%10.28%4.59%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CANOQ
Cano Health
0 of 5 stars
$0.23
-4.3%
N/AN/A$1.22M$3.14B0.002,700Gap Down
SPRC
SciSparc
0 of 5 stars
$1.73
-3.9%
N/A-90.9%$1.22M$2.88M0.003
TCBP
TC Biopharm
0.7876 of 5 stars
$1.86
+4.5%
$1,400.00
+75,168.8%
-99.6%$1.26M$4.76M0.0060Gap Down
ACOR
Acorda Therapeutics
0 of 5 stars
$1.02
-15.0%
N/AN/A$1.27M$117.63M-0.01111Short Interest ↓
Gap Down
High Trading Volume
BDRX
Biodexa Pharmaceuticals
2.5389 of 5 stars
$0.99
-3.9%
$8.00
+708.1%
-96.0%$1.28M$870,000.000.0027Gap Down
SIENQ
Sientra
0 of 5 stars
$0.11
-15.4%
N/AN/A$1.32M$90.55M-0.02304Gap Down
NVTA
Invitae
1.7964 of 5 stars
N/A$1.00
+∞
-99.9%$1.07M$481.58M0.001,700Analyst Report
Gap Down
AKAN
Akanda
0 of 5 stars
$0.12
flat
N/A-90.8%$1.07M$3.94M0.0046Gap Down
EVFM
Evofem Biosciences
0 of 5 stars
$0.02
flat
N/A-99.6%$1.05M$11.39M0.0035News Coverage
Gap Down
CMRA
Comera Life Sciences
0 of 5 stars
$0.03
-22.7%
N/A-94.9%$1.05M$1.00M-0.0712Gap Down

Related Companies and Tools

This page (NASDAQ:VRAX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners